The data were presented on Tuesday in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2019 in Lisbon.
AR101 is an investigational biologic drug for use in oral immunotherapy as a treatment to reduce the frequency and severity of allergic reactions following exposure to peanuts.
The majority of the patients enrolled in the follow-on study could tolerate doses of at least 1,000 mg of peanut protein after they continued daily doses of AR101 for a further 28 weeks, and almost half of all AR101-treated patients tolerated the highest 2,000 mg dose during the exit food challenge. In addition, the patients experienced significant immunological changes, the company said.
Price: 19.96, Change: +0.39, Percent Change: +1.99
|Insider Trends: 90-Days of Insider Buying at Procter...|
|Wedgewood Partners Exits Berkshire Hathaway; Critici...|
|American Express Write-Off Rate Lower in September, ...|
|Update: General Motors, UAW Reportedly Reach Tentati...|
|Midday ETF Update: ETFs, Stocks Climb as Investors F...|